Evidence map›Paper›PMID 31444839›Full record

Trial reportClinical and translational science2020

Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.

Lisa K Stamp, Peter T Chapman, Murray Barclay, Anne Horne, Christopher Frampton, Tony R Merriman, Daniel F B Wright, Jill Drake, Nicola Dalbeth

Open access · goldAbstract readClinical Trial, Phase IVComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Clinical and translational science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Lisa K StampDepartment of Medicine, University of Otago, Christchurch, New Zealand.
Peter T ChapmanDepartment of Rheumatology, Immunology, and Allergy, Christchurch Hospital, Christchurch, New Zealand.
Murray BarclayDepartment of Medicine, University of Otago, Christchurch, New Zealand.
Anne HorneDepartment of Medicine, University of Auckland, Auckland, New Zealand.
Christopher FramptonDepartment of Medicine, University of Otago, Christchurch, New Zealand.
Tony R MerrimanDepartment of Biochemistry, University of Otago, Dunedin, New Zealand.
Daniel F B WrightSchool of Pharmacy, University of Otago, Dunedin, New Zealand.
Jill DrakeDepartment of Medicine, University of Otago, Christchurch, New Zealand.
Nicola DalbethDepartment of Medicine, University of Auckland, Auckland, New Zealand.
University of Otago · NZChristchurch Hospital · NZUniversity of Auckland · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aims of this study were to determine factors that predict serum urate (SU) lowering response to allopurinol and the conversion of allopurinol to oxypurinol, and to determine a minimum therapeutic oxypurinol concentration. Data from 129 participants in a 24-month open, randomized, controlled, parallel-group, comparative clinical trial were analyzed. Allopurinol dose, SU, and plasma oxypurinol concentrations were available at multiple time points. The slope for the association between allopurinol dose and SU was calculated as a measure of sensitivity to allopurinol. The slope for the association between allopurinol dose and oxypurinol was calculated as a measure of allopurinol metabolism. Receiver operating characteristic (ROC) curves were used to identify a minimum oxypurinol concentration predictive of SU < 6 mg/dL. There was a wide range of SU concentrations for each allopurinol dose. The relationship between sensitivity to allopurinol and allopurinol metabolism for each 100 mg allopurinol dose increase varied between individuals. Body mass index (P = 0.023), creatinine clearance (CrCL; P = 0.037), ABCG2 Q141K (P = 0.019), and SU (P = 0.004) were associated with sensitivity to allopurinol. The minimum oxypurinol concentration for achieving the urate target was found to be about 104 μmol/L, but predictive accuracy was poor (ROC curve area under the curve (AUC) 0.65). The minimum therapeutic oxypurinol concentration was found to increase with decreasing renal function. Although there is a positive relationship between change in oxypurinol and change in SU concentration, a minimum therapeutic oxypurinol is dependent on CrCL and cannot reliably predict SU target. Other variables, including ABCG2 Q141K genotype, impact on sensitivity to allopurinol (ACTRN12611000845932).

Indexed as

AgedAllopurinolATP Binding Cassette Transporter, Subfamily G, Member 2Body Mass IndexCreatinineDose-Response Relationship, DrugFemaleGoutGout SuppressantsHumansMaleMiddle AgedNeoplasm ProteinsOxypurinolRenal EliminationROC CurveABCG2 protein, humanAllopurinolATP Binding Cassette Transporter, Subfamily G, Member 2CreatinineGout SuppressantsNeoplasm ProteinsOxypurinolUric Acid

Identifiers

PMID31444839
PMCPMC6951452
OpenAlexW2969365560

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.